ArticleResearch and practice in thrombosis and haemostasis2026
Etiology and management of venous thromboembolism recurrence in patients anticoagulated for venous thromboembolism: a single-center study.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Venous thromboembolism (VTE) recurrence on anticoagulation (ROA) and anticoagulant failure (ACF) are frequently described but poorly defined. Objectives: To determine the incidence and causes of ROA and ACF in patients with VTE. The secondary aim was to describe the management of these cases, including anticoagulation selection and dosing strategies. Methods: Patients with acute VTE enrolled in the Mayo Clinic VTE Registry from 2013 to 2022 were included. Charts of patients with VTE recurrence despite anticoagulation were reviewed. ROA was defined as any new thrombotic event in patients prescribed and recently taking anticoagulants. ACF was defined as ROA in the absence of modifiable risk factors. Results: Of the 4980 patients included, 150 (3.0%) ROA events occurred in 130 patients. Altered absorption ( Conclusion: ROA can affect 3% of patients with VTE. Nearly half of ROA events are preventable with careful review of medications and patient characteristics. When not modifiable, the most used strategy for managing patients with ACF is to transition to another anticoagulant, usually enoxaparin. Our practice strategy for evaluating and managing ROA is outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.